Anton Xavier
Novel target discovery.
•Biotherapeutic (Immunotherapy & ADC) early discovery.
•Biotherapeutic (Immunotherapy & ADC) design and development.
•Intrapreneurship.
•Duties with Pfizer External R&D Innovation & Scouting for novel technologies in therapeutics, diagnostics & medical devices:
(Screen & evaluate early/mid stage (inter)national biotech/pharma technologies that
align with Pfizer’s R&D interest/vision & aid with triaging and funding of such technologies toward
corporate strategic partnerships).
•NYC Bio-entrepreneurship mentor for early stage life science ventures through Pfizer Business
Development and the New York Economic Development Council (ELabNYC, British Consulate, Columbia University).
•Adjunct Faculty member for National Science Foundation (NSF) I-Corps:
The NYC Regional Innovation Node (NYCRIN): Bioentrepreneurship ventures.
Pfizer
Senior Scientist / Scout
Dr Zhinan Xia
Moderna is pioneering messenger RNA Therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions.
Moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. The company plans to develop and commercialize its innovative mRNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients.
Based in Cambridge, Massachusetts, Moderna is privately held and was founded in 2010 by Flagship VentureLabs in association with leading scientists from Boston Children’s Hospital and Massachusetts Institute of Technology.
